Baird Reiterates Bullish View on Sarepta (SRPT) as ESSENCE Starts Dosing

September 29, 2016 7:39 AM EDT
Get Alerts SRPT Hot Sheet
Price: $34.10 +4.41%

Rating Summary:
    16 Buy, 9 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Baird analyst Brian Skorney reiterated an Outperform rating and $102 PT on Sarepta Therapeutic (NASDAQ: SRPT) after the company announced that dosing has started in the Phase 3 ESSENCE study of SRP-4045 and SRP-4053.

Skorney commented, "The one-of-a-kind study is testing two separate exon-skipping agents with the same backbone as eteplirsen in exon 45/53 amenable patients, which comprise about another 16% of DMD patients. ESSENCE, a placebo-controlled, 96-week study, also has potential to be confirmatory of the benefit provided by eteplirsen. If the trial is successful, it could mean more than doubling of Sarepta’s addressable population in the next few years."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $62.24 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Robert W Baird

Add Your Comment